Rahul Banerjee: T-Cell Redirection in AL Amyloidosis – Teclistamab’s Success Ahead of ASH24
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center, shared a post on X about a recent paper by David Sykes and Wilfried Schroyens published in NEJM:
“When it comes to using T-cell redirection in non-MM plasma cell disorders, we’ve focused a lot of our attention on AL amyloidosis…
But cool to see NEJM paper of teclistamab basically curing relapsed TEMPI syndrome, just in time for ASH24!”
“Teclistamab as Successful Treatment of Relapsed TEMPI Syndrome”
Authors: David Sykes and Wilfried Schroyens.
More posts featuring Rahul Banerjee.
Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency at the University of Pennsylvania health system.
He completed his fellowship in haematology and oncology from the University of California, San Francisco. He has authored over 70 peer-reviewed publications. His clinical interests include multiple myeloma.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023